Russia confirms record 11,656 COVID-19 cases in 24 hrs | WeForNews | Latest News, Blogs Russia confirms record 11,656 COVID-19 cases in 24 hrs – WeForNews | Latest News, Blogs
Connect with us

Disaster

Russia confirms record 11,656 COVID-19 cases in 24 hrs

Russia’s consumer rights and human well-being watchdog said on Monday that 247,842 people were under medical observation as of Sunday.

Published

on

RUSSIA CORONAVIRUS

Moscow, May 11 : Russia has reported a record 11,656 new COVID-19 cases over the past 24 hours, raising the total number of infections to 221,344, the country’s coronavirus response centre said ont Monday.

The more than 10,000 single-day increase has now entered the ninth day, Xinhua news agency.

The death toll grew by 94 to 2,009, while 39,801 people have recovered, including a record of 5,495 over the last 24 hours, the statement said.

Moscow, the country’s worst-hit region, confirmed 6,169 new cases in the past 24 hours, taking its total to 115,909.

Russia’s consumer rights and human well-being watchdog said on Monday that 247,842 people were under medical observation as of Sunday.

More than 5.6 million lab tests for COVID-19 have been conducted across the country so far, it added.

Disaster

Covid-19: Caseload Crosses 80 Lakh Mark With 48,648 Fresh Cases

Covid-19 death toll rose to 1,21,090 with 563 new fatalities and national recovery rate to 91.15 per cent

Published

on

Coronavirus India

India saw 48,648 new coronavirus infections being reported in a day taking the Covid-19 caseload to 80,88,851, while active cases fell below 6,00,000 and the national recovery rate crossed 91 per cent, according to the Union Health Ministry data updated on Friday.

The Covid-19 death toll in the country climbed to 1,21,090 with 563 new fatalities, the data updated at 8 am showed.

A total of 73,73,375 people have recuperated from Covid-19 so far pushing the national recovery rate to 91.15 per cent while the case fatality rate stands at 1.50 per cent.

There are 5,94,386 active cases of coronavirus infection in the country as on date which comprises 7.35 per cent of the total caseload, the data stated.

India’s Covid-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23 and 40 lakh on September 5 .
It went past 50 lakh on September 16, 60 lakh on September 28, 70 lakh on October 11 and crossed 80 lakh on October 29.

According to the ICMR, a cumulative total of 10,77,28,088 samples have been tested up to October 29 with 11,64,648 samples being tested on Thursday.

The 563 new fatalities include 156 from Maharashtra, 61 from West Bengal, 53 from Chhattisgarh, 45 from Karnataka, 35 from Tamil Nadu, 27 from Delhi and 26 from Kerala.

A total of 1,21,090 deaths reported so far in the country including 43,710 from Maharashtra followed by 11,091 from
Karnataka, 11,053 from Tamil Nadu, 6,983 from Uttar Pradesh, 6,725 from West Bengal, 6,659 from Andhra Pradesh, 6,423 from Delhi, 4,168 from Punjab and 3,705 from Gujarat.

The health ministry stressed that more than 70 per cent of the deaths occurred due to comorbidities.

“Our figures are being reconciled with the Indian Council of Medical Research,” the ministry said on its website, adding that state-wise distribution of figures is subject to further verification and reconciliation.

Continue Reading

Cities

Delhi records highest single-day spike of 5,891 COVID-19 cases; death toll reaches 6,470

Published

on

By

Coronavirus Treatment

New Delhi, Oct 30 : The highest single-day rise of 5,891 fresh COVID-19 cases on Friday took Delhi”s tally of infection to over 3.81 lakh, authorities said.

This was the third consecutive day when over 5,000 cases have been reported in a day in the city.

On Thursday, Delhi had recorded 5,739 cases of coronavirus infection.

The national capital also recorded 47 new fatalities on Friday, pushing the death toll to 6,470, according to a bulletin issued by the Delhi health department.

As many as 59,641 tests for detection of COVID-19 was conducted on Thursday. The number of active cases in the city has risen to 32,363 on Friday from 30,952 the previous day, it stated.

The bulletin said the total number of cases in the city has climbed to 3,81,644.

Continue Reading

Disaster

Sanofi, GSK to supply COVAX with 200 mn doses of COVID-19 vaccine

Translate Bio has established mRNA manufacturing capacity and Sanofi expects to be able to supply annual capacity of 90 to 360 million doses.

Published

on

COVID-19 Vaccine

New Delhi, Oct 29 : Sanofi and GSK have signed a Statement of Intent with Gavi, the legal administrator of the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual COVID-19 vaccines.

Sanofi and GSK intend to make available 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine, if approved by regulatory authorities and subject to contract, to the COVAX Facility.

Both Companies intend to contribute to COVAX’s ambition to ensure successful COVID-19 vaccines reach those in need, whoever they are and wherever they live, once they obtain appropriate approvals.

“To address a global health crisis of this magnitude, it takes unique partnerships. The commitment we are announcing today for the COVAX Facility can help us together stand a better chance of bringing the pandemic under control,” said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur.

“This moment also reflects our long-term commitment to global health and ensures our COVID-19 vaccines are affordable and accessible to those most at risk, everywhere in the world.”

Roger Connor, President of GSK Vaccines added, “Since we started working on the development of COVID-19 vaccines, GSK has pledged to make them available to people around the world. We are proud to be working with Sanofi to make this adjuvanted recombinant protein-based vaccine available to the countries signed up to the COVAX Facility as soon as possible – this has the potential to be a significant contribution to the global fight against COVID-19.”

The COVAX Facility is part of COVAX, a global collaboration of governments, global health organisations, businesses and philanthropic organisations working to accelerate development, production, and equitable access to COVID-19 vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO and forms the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. More than 180 countries and economies have signed onto the COVAX Facility to get timely and cost-effective access to vaccines to meet the global scale of the COVID-19 pandemic.

Through the COVAX Facility’s efforts, vaccines will be distributed in participating countries through the WHO’s recently published Allocation Framework, and the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) Values Framework which has begun to frame future guidance on vaccine use. These allocation principles aim to ensure that people in all parts of the world will get access to COVID-19 vaccines once they are available.

Sanofi and GSK initiated a Phase 1/2 study on September 3 with a total of 440 subjects enrolled, and anticipate first results in early December 2020, to support the initiation of a pivotal Phase 3 study before the end of the year. If these data are sufficient for licensure application, it is planned to request regulatory approval from the first half of 2021. In parallel, the Companies are scaling up manufacturing of the antigen and adjuvant respectively.

In addition to the recombinant protein-based vaccine in collaboration with GSK, Sanofi is developing a messenger RNA vaccine in partnership with Translate Bio. With several innovative vaccine platforms currently being investigated across the industry, mRNA is considered among the most promising.

Preclinical data showed that two immunizations of the mRNA vaccine induced high neutralizing antibody levels that are comparable to the upper range of those observed in infected humans. Sanofi expects the Phase 1/2 study to start in the fourth quarter of 2020, with earliest potential approval in the second half of 2021. Translate Bio has established mRNA manufacturing capacity and Sanofi expects to be able to supply annual capacity of 90 to 360 million doses.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.